CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 662 enrolled
Drug / intervention
CD2475/101 40 mg +2 moredrug
Likely dose
CD2475/101 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01320033
NCT01320033Phase 2Completed
CompareCT.gov

A Multi Center, Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group Study Comparing the Efficacy and Safety of CD2475/101 40 mg Tablets Versus Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjects With Acne Vulgaris

Galderma R&D·interventional·Posted Mar 22, 2011·Updated Feb 18, 2021

In Brief

A Phase 2 clinical trial evaluating CD2475/101 40 mg, Doxycycline 100 mg, and 1 other intervention for Acne Vulgaris. Completed, enrolled 662 participants across 31 sites.

Detailed Summary

The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory lesion counts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 22, 2011
Enrollment StartMar 29, 2011
Primary CompletionJan 3, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.3 years ago

Interventions

CD2475/101 40 mgdrug

Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.

Doxycycline 100 mgdrug

Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks

Placebodrug

Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.